Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

Abstract

Introduction:

Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer.

Methods:

Her-2-negative breast cancer patients with tumours larger than 2 cm were eligible for dose-escalation trial (classic 3+3 method).

Results:

The recommended phase II dose (RP2D) was 150 mg BID of nintedanib combined with standard dose of weekly paclitaxel followed by adriamycin plus cyclophosphamide. The dose-limiting toxicity was transaminase elevation. At the RP2D, the dose intensity was ∼100%. The pathologic complete response was 50%.

Conclusions:

The combination allows the delivery of full-dose intensity, while efficacy seems promising.

Despite the early diagnosis screening campaigns, long-term relapse rates of HER-2-negative breast cancer range from 25% (hormone-receptor positive; Davies et al, 2013) to >40% (triple-negative breast cancer; Foulkes et al, 2010). Combinations of different cytotoxic agents or introduction of novel therapeutic schedules seem to have reached a plateau in long-term disease control (Swain et al, 2013; Earl et al, 2014). Clearly, novel therapeutic alternatives are needed.

Antiangiogenic agents are an attractive therapeutic strategy as their therapeutic effect is more dependent on the effects on the microenvironment than on the underlying oncogenic mutation (Weis and Cheresh, 2011). Breast cancer seems to be clustered into many different subtypes characterised by many non-overlapping patterns of genetic aberrations (Curtis et al, 2012; Shah et al, 2012); thus, antiangiogenic agents may be useful across several of those subtypes.

Recent randomised trials have proven increased efficacy of adding bevacizumab, a monoclonal antibody against VEGF, to standard neoadjuvant chemotherapy in HER-2-negative early breast cancer (Bear et al, 2012; von Minckwitz et al, 2012). A second class of antiangiogenic agents, small molecules with multi-tyrosine kinase inhibitor activity that target several pro-angiogenic axes (TKIs), has been studied in breast cancer as well. First-generation agents of this class, like sunitinib or sorafenib, increased the progression-free survival (Baselga et al, 2012; Bergh et al, 2012). However, in the long term, this was not translated into higher survival rates (Baselga et al, 2012; Bergh et al, 2012). One possibility accounting for these disappointing results is that these regimens were highly toxic. Second, the chemotherapy total dose intensity was significantly reduced, probably explaining the detrimental effects.

Nintedanib is a novel agent of this therapeutic class. It has activity against VEGFR1-3, PDGFRA/B, FGFR1-3 and other pro-oncogenic kinases such as RET or FTL3 in the low nanomolar range. Preclinical studies suggest a lower Km than their predecessors against pro-angiogenic kinases (Boehringer Ingelheim, GmbH, 2009). Clinical studies in combination with chemotherapy in other malignancies where other antiangiogenic drugs did not achieve improvement in overall survival suggest improved toxicity profile and long-term efficacy (Ledermann et al, 2011; Reck et al, 2014).

Thus, we aimed to determine the recommended phase II dose (RP2D) of nintedanib in combination with standard chemotherapy for neoadjuvant breast cancer and to study its tolerability during a full course of neoadjuvant chemotherapy. As a secondary objective, we describe the anti-tumour efficacy, reported as pathologic complete response. This trial was conducted with the aim of studying the efficacy of nintedanib in breast cancer in a randomised trial. The combination showed an excellent tolerance, allowing delivery of full-dose intensity, and showed an impressive preliminary activity.

Materials and Methods

Patients

Women aged >18 years with histologically confirmed HER-2-negative resectable breast cancer were eligible. Key inclusion criteria included: (1) signed informed consent form; (2) primary tumour over 2 cm on its longer diameter (measured by MRI; any nodal status and multicentricity were allowed, as long as the disease was deemed resectable by a multidisciplinary committee); (3) HER-2-negative disease; (4) ECOG 0–1; (5) adequate liver, haematologic and renal function defined by usual phase I criteria. Patients with previous treatment of any kind for breast cancer (excluding patients adequately treated >5 years ago from a previous breast cancer), undergoing hormonal replacement or contraceptives, concurrent or previous malignancy of any kind up to 5 years before diagnosis (except from non-melanoma skin cancer or in situ carcinoma of the breast or cervix), concurrent serious medical conditions, or patients undergoing anticoagulation/antiplatelet therapy (except low-dose heparin or <325 mg per day aspirin) or with a history of haemorrhagic/thromboembolic event clinically significant in the last 6 months were excluded. Patients with recent major surgery (4 weeks) were not candidates for this trial.

The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice Guidelines, the Declaration of Helsinki and applicable local regulatory requirements and laws. The protocol was approved by the Institutional Review Board.

Study design, treatment and procedures

This was an open-label, prospective, multicentric dose-finding study. The trial was an investigator-sponsored study.

The primary objectives were to determine the RP2D and study the tolerability and safety of the combination of nintedanib with weekly paclitaxel, followed by adriamycin plus cyclophosphamide (4 × ). The secondary objective was to study the activity of the combination. The escalation followed a classic 3+3 scheme. The treatment schedule and dosages are depicted and described in Figure 1A. Two rules were considered: (1) paclitaxel, adriamycin or cyclophosphamide doses were fixed at standard doses and not to be escalated, despite of the dose level achieved for nintedanib; and (2) the maximum-tolerated dose of nintedanib in combination with paclitaxel should be below 150 mg BID, the planned randomised phase II trial would not be conducted, as according to preclinical and single-agent phase I studies, the plasma levels would be insufficient to achieve pharmacodynamic activity (Boehringer Ingelheim, GmbH, 2009; Mross et al, 2010). Neoadjuvant adriamycin plus cyclophosphamide were administered without nintedanib, due to the potential additive cardiotoxic properties.

Figure 1.

Trial schedule. Patients received oral nintedanib twice per day during the 12 courses of weekly paclitaxel. The morning dose of nintedanib of the paclitaxel days was omitted due to previous preclinical pharmacokinetic interaction observations. One week after the last nintedanib dose (2 weeks after the last paclitaxel infusion), adriamycin plus cyclophosphamide was started, every 21 days. Surgery was programmed a minimum of 4 weeks after the last chemotherapy dose, and in any case, 5 weeks since the last nintedanib dose. Radiation and/or hormonal therapy were administered after surgery according to physician's choice.

The primary end point was to determine the incidence and nature of dose-limiting toxicities (DLTs) of nintedanib in combination with neoadjuvant paclitaxel followed by adriamycin/cyclophosphamide graded according to NCI CTCAE v4.0 (NCI). The secondary end point was pathologic complete response measured by the Miller and Payne criteria (Ogston et al, 2003).

Patients were staged with conventional procedures; a LVEF was determined with ultrasound before registration. The patients were visited weekly during the first 3-week cycle and on days 1 and 15 subsequently, for physical and haematologic toxicity assessment. Detailed schedules for dose reductions or drug hold are provided in Supplementary Materials and Methods. The DLT evaluation period was from day 1 to 21; however, no escalation was performed until all patients in one dose level completed two cycles.

Statistical studies

Safety was evaluated in all patients who received at least one dose of study medication. Efficacy was evaluated in patients who received at least one cycle of treatment (21 days). Nonparametric test was used due to the sample size. Dose intensity was calculated as the total delivered dose divided by the planned dose, for each agent.

Results

Dose escalation, toxicity and dose delivery

Basic patient demography is depicted in Table 1. Three patients were enroled in level 1 (150 mg BID of nintedanib); no DLTs were observed. We then escalated to level 2 (200 mg BID). One of the two patients experienced a DLT, consisting on grade 3 ALT elevation on day +8. The patient withdrew consent and came off trial. We recruited a third patient who on day +8 presented with a DLT, consisting on G4 ALT elevation plus G3 AST and GGT elevation. Nintedanib was held until recovery to <G2 (14 days later); paclitaxel was resumed 7 days earlier. The dose was reduced to level 1 and the patient continued without significant side effects. We finally recruited three more patients in dose level 1. No further DLTs were registered. Thus, 80 mg m² of weekly paclitaxel plus 150 mg BID of nintedanib was established as the RP2D.

Table 1. Patient demographics.

Characteristics	Data
Number of patients	9
Age (median; range)	48 (38–66)
Menstrual status
Pre-menopausal	1 (11%)
Post-menopausal	8 (89%)
ECOG (0/1)	9/0
Stage
IIA	2 (22%)
IIB	4 (45%)
IIIA	2 (22%)
IIIB	1 (11%)
Grade (1/2/3)	3/3/3
Tumour size (median; range)	3 cm (2.7–6.5)
Node positive	7 (78%)
Hormone positive	7 (78%)
Triple negative	2 (22%)

Abbreviation: ECOG=Eastern Cooperative Oncology Group.

Besides one G3 neutropenia and two grade 3 lymphopenia, no G3 or non-tolerable G2 toxicity was reported in the 24 cycles administered in level 1. The main toxicity events are detailed in Table 2. Of note, hand–foot syndrome or blood pressure elevation, classic toxicities of this drug class, were absent or very mild, respectively, in level 1; in level 2, only one grade 3 hypertension was registered (Table 2).

Table 2. Toxicity events deemed possibly related (grade 2 or higher).

Dose level 1 (N=6 patients)
Event	Grade 2—N	Grade 2—%	Grade 3—N	Grade 3—%
ALT increased	1	16.7	0	0
Alopecia	5	83.3	0	0
Diarrhoea	1	16.7	0	0
Fatigue	1	16.7	0	0
GGT increased	1	16.7	0	0
Headache	1	16.7	0	0
Hypertension	3	50	0	0
Lymphopenia	0	0	1	16.7
Neutropenia	0	0	1	16.7
Peripheral sensory neuropathy	1	16.7	0	0

Dose level 2 (N=3 patients)
Event	Grade 2—N	Grade 2—%	Grade 3—N	Grade 3—%	Grade 4—N	Grade 4—%
ALT increased	0	0	1	33.3	1	33.3
Alopecia	1	33.3	0	0	0	0
AST increased	0	0	1	33.3	0	0
Bilirubin elevation	1	33.3	0	0	0	0
Diarrhoea	1	33.3	0	0	0	0
Fatigue	1	33.3	0	0	0	0
GGT increased	1	33.3	2	66.7	0	0
Hypertension	1	33.3	1	33.3	0	0

Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transpeptidase.

The dose delivery in level one was almost complete: 99.9 and 97.4% of the planned nintedanib and paclitaxel doses were administered. No dose reductions were needed. There were two 1-week paclitaxel dose delays related to toxicity (G2 neutropenia and G1 fever, the latter deemed unrelated to study medication by the investigators).

Efficacy

Eight patients were evaluable. The pathologic complete response (breast plus axilla) was 50%. Two out of six hormone-receptor-positive patients (33%), and two out of two triple-negative patients, achieved pathologic complete response. The remainder four patients achieved G2 (three patients, 37.5%) and G3 (one patient, 12.5%) Miller and Payne response. Six out of eight patients (75%) underwent conservative surgery.

Discussion

TKIs such as sorafenib or sunitinib have been developed in breast cancer. However, the interpretation of the efficacy data is complex, as in many cases the concurrent administration with chemotherapy led to excessive toxicity, compromising adequate delivery of dose intensity, which is a key factor for chemotherapy-derived benefit (Budman, 2004; Baselga et al, 2012; Bergh et al, 2012). Novel molecules such as nintedanib show a better preclinical profile and thus could overcome such limitation (Boehringer Ingelheim, GmbH, 2009). This feature would make it a potential good therapeutic option, given the activity of antiangiogenics in this malignancy.

We present here a phase I trial of the combination of nintedanib with standard treatment for neoadjuvant breast cancer. The RP2D is 150 mg per day BID combined with weekly paclitaxel (80 mg m²), followed by AC. At this dose level, the observed toxicity is virtually indistinguishable from that reported for weekly paclitaxel alone. Only minor, reversible (without treatment discontinuation) transaminases elevation was noticed. Indeed, the dose intensity of both drugs was close to 100%. Interestingly, class-specific effects such as hypertension of hand–foot syndrome were not observed for nintedanib at the RP2D. The efficacy at this dose level, in a cohort of patients with locally advanced breast cancer and mostly node positive, is very promising despite the low number of patients, achieving conservative surgery in most cases, and an unusually high rate of pathologic complete response. In light of these results, a randomised phase II trial in neoadjuvant HER-2-negative breast cancer with a target enrolment of 130 patients is ongoing. Of note, in this study, the response was measured following the Miller and Payne system as the response rate was not a primary end point; however, the randomised trial efficacy will be assessed based on the updated Symmans and Pusztai criteria, which may reflect more accurately the true activity of the combination (Symmans et al, 2007).